Myelofibrosis and Anemia Research Study
Part of Blood & lymphatic clinical trials.
This study follows people with myelofibrosis and anemia who are starting a new treatment. It aims to learn more about the disease and how treatments work in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of myelofibrosis (either primary or caused by another blood disorder).
- You have anemia at the time you join the study (your doctor confirms this).
- You are about to start your first or a later treatment for myelofibrosis.
- You agree to join the GSG-MPN Bioregistry and to fill out questionnaires about how you feel.
- You sign a consent form within six weeks of starting your myelofibrosis treatment.
- You are not planning to have a stem cell transplant or taking part in another treatment study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from people diagnosed with myelofibrosis to understand how the disease affects them over time. It may help researchers learn more about the condition and improve future care.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This study is a “registry,” meaning it collects information about adults with specific types of myeloproliferative neoplasms (MPNs). It helps researchers better understand these diseases and may improve future care.
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
This is a research registry for people who have certain blood cancers called myeloproliferative neoplasms (MPNs). It helps researchers learn about the disease over time and may help future studies find and compare patients.
Hear when a new Primary Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.